Skip to main content

Table 3 Outcomes of Anti-Cancer Chemotherapy (Anti-CCT) and Anti-MTB Chemotherapy

From: Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study

Characteristic Patients
All LC (SCLC/NSCLC) CRC Other
(n = 30) (n = 15, 5/10) (n = 10) (n = 5)
Initial concurrent anti-CCT regimen, n
 Intensive cytotoxic regimen and targeted agenta 4 0 3 1
 Intensive cytotoxic regimenb 19 10 (5/5) 6 3
 Single targeted agentc 2 2 (0/2) 0 0
 Single cytotoxic agentd 5 3 (0/3) 1 1
Best response on anti-CCT after commencing concurrent chemotherapy, n
 CR 1 0 1 0
 PR 10 5 (4/1) 3 2
 SD 5 2 (0/2) 3 0
 PD 6 4 (0/4) 2 0
 NE 8 4 (1/3) 1 3
ORR (%)e 36.7 33.3 (80.0/10.0) 40.0 40.0
Main anti-MTB chemotherapy, n
 2HREZ/7HRf 15 8 (3/5) 4 3
 6HRE/6HRg 7 2 (0/2) 4 1
 Levofloxacin-based 8 5 (2/3) 2 1
Duration of anti-MTB treatment (days), median (range) 275.0 (72–637) 274.0 (90–469) [274 (183–469)/255 (90–310)] 259.0 (72–539) 368.0 (273–637)
Duration of concurrent chemotherapy (days), median (range) 157.5 (13–408) 117.0 (20–245) [93 (20–207)/121 (48–245)] 168.5 (13–408) 155.0 (51–376)
MTB treatment outcomes, n (%) All LC CRC Other
 Cured 20 (66.7) 10 (66.7) 6 (60.0) 4 (80.0)
 Completed 1 (3.3) 0 1 (10.0) 0
 Died 9 (30) 5 (33.3) 3 (30.0) 1 (20.0)
 Failed 0 0 0 0
 Not evaluated 0 0 0 0
Success (%)h 70.0 66.7 70.0 80.0
  1. Abbreviations CI confidence interval, CR complete response, CRC colorectal cancer, E ethambutol, EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor, H isoniazid, LC lung cancer, MTB Mycobacterium tuberculosis, NE not evaluable, ORR overall response rate, PD progressive disease, PR partial response, R rifampicin, SD stable disease, Z pyrazinamide
  2. aTwo cytotoxic agents combined with targeted therapy (bevacizumab or trastuzumab)
  3. bTwo cytoxic agents
  4. cErlotinib
  5. dSingle cytoxic agent (S-1, vinorelbine, or pemetrexed)
  6. eCR + PR
  7. fDaily drug combination containing HREZ for 2 months, followed by daily HR for 7 months
  8. gDaily drug combination containing HRE for 6 months, followed by HR for 6 months
  9. hCured + completed